Urothelial Carcinoma — Trials

Urothelial Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

623 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 236
Recruiting: 117
Ph III recruiting: 14
Growth YoY: +37.5%
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (99)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07821177	Bladder Preservation or Cystectomy for MIBC	active not recruiting	Early Phase 1	20	Dana-Farber Cancer InstituteOTHER	1	Sep 15, 2026	clinicaltrials
NCT02812420	Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery	active not recruiting	Early Phase 1	54	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials